Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01699672
Other study ID # REK2012/1238
Secondary ID
Status Terminated
Phase N/A
First received September 21, 2012
Last updated January 25, 2017
Start date October 2012
Est. completion date July 2015

Study information

Verified date January 2017
Source Norwegian University of Science and Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim of the current study is to investigate whether the addition of a standardized,group-based educational program to the information provided by health care personnel improves cancer patients' knowledge level about their disease, planned treatment and common side-effects of the treatment.

Secondary aims are to investigate if the addition of the educational program increases the likelihood of completing treatment as planned, reduces level of anxiety, reduces the frequency of serious side effects, increases patient reported health related quality of life, and increases the degree of patient satisfaction with respect to how they have received the information before, during and after treatment.


Description:

There are strong indications that group-based information provides better information for cancer patients about their disease, treatment options - and potential benefits and side effects of the planned therapy than information provided during a regular doctor consultation.

The investigators believe that standardizing and repeating the information as well as having more time for questions in an open environment for reflections will improve the amount of information patients can perceive. Furthermore, all patients will be given written information.

Better-informed patients may be more motivated and may contact health care personnel earlier than other patients when they develop side effects. This may reduce the risk of serious treatment-related complications and increase the chances of patients completing the planned treatment. But none have compared to what extent an organization like Vardesenteret improves the patients' knowledge and whether patients are more satisfied with these methods for informing them. Results from studies on the influence of patient anxiety and distress on patient's abilities to perceive information are conflicting.Two large groups of relatively homogenous cancer patients are patients with lower-stage breast cancer patients who are eligible for adjuvant chemotherapy and patients with localized prostate cancer eligible for curative radiotherapy.


Recruitment information / eligibility

Status Terminated
Enrollment 98
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

- Breast cancer patients that are candidates for adjuvant chemotherapy after surgery.

- Prostate cancer patients that are candidates for curative radiotherapy

- Signed informed consent

- Patient expected to be able to complete the planned treatment and the study procedures

- 18years or older

Exclusion Criteria:

-Patients not fulfilling inclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Group information
The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.

Locations

Country Name City State
Norway St Olavs Hospital Trondheim

Sponsors (2)

Lead Sponsor Collaborator
Norwegian University of Science and Technology St. Olavs Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Knowledge Knowledge questionnaires specially made for the study. Constructed as statements with response categories; correct, false and don´t know. 1 week
Primary Knowledge Knowledge questionnaires specially made for the study. Constructed as statements with response categories; correct, false and don´t know. 2 weeks
Primary Knowledge Knowledge questionnaires specially made for the study. Constructed as statements with response categories; correct, false and don´t know. 9 weeks
Secondary Quality of Life European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire C30 9 weeks
Secondary Patients Subjective state of information European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire INFO 25 1 week
Secondary Patients Subjective state of information European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire INFO 25 2 weeks
Secondary Patients Subjective state of information European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire INFO 25 9 weeks
Secondary Anxiety STAI-State and Trait Anxiety Inventory 1 week
Secondary Anxiety STAI-State and Trait Anxiety Inventory 2 weeks
Secondary Anxiety STAI-State and Trait Anxiety Inventory 9 weeks
Secondary Adverse events CTCEA, Common Terminology Criteria for Adverse Events 2 weeks
Secondary Adverse events CTCEA, Common Terminology Criteria for Adverse Events 9 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2